Thus, CTL responses specific for MHC class I HER-2/neu epitopes have been observed in some patients with cancer and HER-2/neu-specific IgG antibodies have been detected in the sera of patients with HER-2/neu+ cancers (Disis et al, 1994a,1994b; Yoshino et al, 1994;Knutson et al, 2001). Here, ERBB2 is linked to cancer.